For this event Cambridge Network exploring the future of B2B sales in the age of AI with Jean-Michel Van of RoverLead. Sales appears to be changing, and in this event you will learn:
About us:
Tessellate Bio is a pioneering and fast-growing international biotechnology company, focusing on targets to address cancers that depend on synthetic lethality (SL) mechanisms.
We are seeking to expand our innovative pipeline by exploiting additional targets for patients’ population with unmet needs. Our Lab in Stevenage Bioscience Catalyst supports target validation and molecular pharmacology activities to grow the Tessellate business.
About the role:
|
First Letting Secured at Sidney Sussex Building, Chesterford Research Park
Three-storey, multi-occupancy R&D building welcomes Camena Bioscience
|
Silverstone, UK, 30 April 2026: Lab Thread Ltd, a UK-based life science software company, today announced the worldwide commercial release of its Unified Lab Software Platform. By linking functional modules including molecular biology tools, electronic notebook (ELN) records and laboratory information management (LIMS) functionality, Lab Thread creates a simple, secure digital thread – bringing together scientific teams, data and entire laboratory workflows to accelerate biological research and advance scientific discovery.
LONDON, UK and UTRECHT, the Netherlands – April 30, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search assignment for Laigo Bio (“Laigo”) and is pleased to announce the placement of Dr. Richard C.A. Sainson as its new Chief Scientific Officer (CSO).
Does sales performance matter to you - whether you sell, lead sales teams or are responsible for business performance?
There’s a lot of noise about how sales is changing, but it can be hard to know what’s real and what it means for you, your team, and your business. It’s true that B2B sales is always evolving, but not always in the ways we might think or the hype suggests. Join us for a practical session that cuts through the noise to explore what’s really changing—and, as importantly, what isn’t.
We are Alloy Therapeutics—a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners, we democratize access to pre-competitive tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics. The company facilitates affordable, non-exclusive access to the entire drug discovery community from academic scientists, small and medium biotech, to the largest biopharma.
Virtual business development & licensing event.
Biotechgate Digital Partnering is designed to support the business development & licensing of Pharma, Biotech, Medtech and Digital Health companies. Join five days of virtual partnering and establish new global connections thanks to pre-arranged one-on-one Zoom meetings in our business forum.
*One Nucleus members can upgrade to Premium access for free. Please contact [email protected] for the details.
Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar demonstrates how integrated strategies help overcome these hurdles and support informed preclinical decisions.